(Bermuda) Gap Biography and Net Worth

Major Shareholder of Centessa Pharmaceuticals

(Bermuda) Gap is the Major Shareholder of Centessa Pharmaceuticals.

How do I contact (Bermuda) Ltd Gap?: The corporate mailing address for Gap and other Centessa Pharmaceuticals executives is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. Centessa Pharmaceuticals can also be reached via phone at 44-73-9178-9784 and via email at [email protected]. Learn More on (Bermuda) Ltd Gap's contact information.
Has (Bermuda) Ltd Gap been buying or selling shares of Centessa Pharmaceuticals?: (Bermuda) Ltd Gap has not been actively trading shares of Centessa Pharmaceuticals over the course of the past ninety days. Learn More on (Bermuda) Ltd Gap's trading history.
Who are Centessa Pharmaceuticals' active insiders?: Centessa Pharmaceuticals' insider roster includes Tia Bush (Insider), Francesco De Rubertis (Director), (Bermuda) Gap (Major Shareholder), David Grainger (Insider), Aaron Kantoff (Director), and Saurabh Saha (CEO). Learn More on Centessa Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Centessa Pharmaceuticals?: In the last year, insiders at the sold shares 12 times. They sold a total of 380,458 shares worth more than $5,855,386.13. The most recent insider tranaction occured on October, 25th when insider Gregory M Weinhoff sold 11,742 shares worth more than $180,591.96. Insiders at Centessa Pharmaceuticals own 11.6% of the company. Learn More about insider trades at Centessa Pharmaceuticals.
Information on this page was last updated on 10/25/2024.

(Bermuda) Ltd Gap Insider Trading History at Centessa Pharmaceuticals

(Bermuda) Ltd Gap Buying and Selling Activity at Centessa Pharmaceuticals

Centessa Pharmaceuticals Company Overview

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Today's Range

Now: $16.74

$16.46

$17.35

50 Day Range

MA: $16.03

$15.04

$18.08

2 Week Range

Now: $16.74

$5.58

$18.74

Volume

622,655 shs

Average Volume

509,086 shs

Market Capitalization

$1.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

From Darwin | Ad

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!